January 2026
Galenica Group
Strong sales growth despite one sales day less
1,900
2,021
+5.0%1,995
+5.9%2,140
3,921
+5.5%4,136
H1 2024 H2 2024 2024 H1 2025 H2 2025 2025
Galenica Group
Sales growth supported by acquisition of Labor Team
Net sales (in million CHF)+5.5%
3'921
4'136
+4.8%
3'180
3'333
+6.8%
1'700
1'816
Galenica Group Products & Care Logistics & IT
Galenica Group
Sales growth across all business areas
Net sales (in million CHF) | 2025 | 2024 | change |
Pharmacies Omni-Chanel | 1'473.3 | 1'404.3 | +4.9% |
Products & Brands | 194.2 | 190.2 | +2.1% |
Services & Production | 119.9 | 115.2 | +4.0% |
Diagnostics | 40.7 | 0.0 | |
Products & Care | 1'816.4 | 1'700.2 | +6.8% |
Wholesale | 3'255.3 | 3'105.2 | +4.8% |
Logistics & IT Services | 79.6 | 77.5 | +2.8% |
Logistics & IT | 3'332.6 | 3'180.5 | +4.8% |
Galenica Group | 4'135.6 | 3'921.1 +5.5% |
Pharmacies Omni-Channel
Strong sales growth with prescription medicines
Net sales (in million CHF)1,404
+4.9%
1,473
Portfolio of local pharmacies expanded by 5 locations: expansion impact1 of +1.6%
+5.2%
678
727
713
+4.6%
760
Generics substitution rate remains with 78.1% at high level (79.2% at Dec 2024).
H1 2024 H2 2024 2024 H1 2025 H2 2025 2025
The effect of net expansion is calculated only including point of sales without a full year period comparison (acquisitions, openings and closure of pharmacies)
Products & Brands
Growth dampend by bridging stock sales in prior year
Net sales (in million CHF)158
149
76
79
79
73
15
36
41
100 90
24 17
190
+2.1%
+0.7% +3.7%
101 93
21
194
-12.6%
+6.2%
Swiss market:
− Growth due to expansion of +6.1%1
− Organic growth of CH +0.1%
− Growth of CH market sales2 -0.6%
− Market share2 of 10.7%
H1 2024 H2 2024 2024 H1 2025 H2 2025 2025
Expansion impact related new licence agreements in Jan. 2025, the effect of net expansion is calculated only including business activities without a full year period comparison (acquisitions and new license agreements)
Product sales to end customers of Verfora, Spagyros and Padma products (like-for-like, streetprices), IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, Consumer Health market YTD Dec. 2025
Services & Production
Strong sales growth in homecare business
Net sales (in million CHF)+4.3% +3.8%
56
60
58
62
115
+4.0%
120
H1 2024 H2 2024 2024 H1 2025 H2 2025 2025
Consistent, strong growth with services for homecare organizations and nursing homes
Wholesale
Further Market share gains in pharmacies segments
Net sales (in million CHF)1,496 1,609
435 464
972 1'055
3,105
900
2,028
+4.8%
+5.6% +4.2%
1,580 1,676
461 474
1'027 1'109
3,255
934
2,136
+3.9%
+5.3%
89 89 178 92 93
185
+3.8%
H1 2024 H2 2024 2024 H1 2025 H2 2025 2025
Logistics & IT Services
Solid growth with Prewholesale
Net sales (in million CHF)+2.8%
39
39
+1.8%
39
+3.8%
40
77 80
H1 2024 H2 2024 2024 H1 2025 H2 2025 2025
Solid growth with prewholesale distribution
Swiss pharmaceutical market
Strong growth despite one sales day less
in million CHF
760
740
720
700
680
660
640
620
600
580
560
540
520
500
Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez
Total market growth
CHF 8,073.3 million (+5.0%)
200.8 million packs (+0.4%)
CHF 1,959.3 million (+5.0%)
15.5 million packs (-0.1%)
24.3%
CHF 61.0 million (-3.3%)
5.7 million packs (-4.6%)
0.8%
26.5%
43.5%
CHF 3,512.4 million (+5.3%)
132.3 million packs (+0.7%)
CHF 2,140.8 million (+3.9%)
45.5 million packs (+0.2%)
5.0%
CHF 399.8 million (+9.3%)
1.8 million packs (-3.7%)
Consumer healthcare market December 2025
2.9%
12.6%
19.3%
65.2%
Total market
CHF 2,630.7 million
-0.4%
-0.3%
-1.9%
+1.2%
-1.1%
Non-medication segment
-0.8%Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices
© IQVIA - Consumer Health market December 2025
Disclaimer
Disclaimer Galenica
Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward- looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted develop-ments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.
Disclaimer IQVIA © 2026, IQVIA AG
All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA AG. Terms used in connection with data/figures such as "patient", "doctor", "medical practice", "prescriber", or "pharmacy" do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws).
IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined.